STOCKSURGICAL & MEDICAL INSTRUMENTS & APPARATUSUpdated 2026-07-26
Here’s whether NovoCure Limited Ordinary Shares (NVCR) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.12% over 10 days); RSI 51 — healthy momentum range; strong 1-year return of +40.8%; 3-month momentum positive (+41.5%). Currently 17.7% off its 52-week high. Score: +7/7.
NVCR is in a confirmed uptrend, trading above both its 50-day ($16.72) and 200-day ($13.74) moving averages. An RSI of 51.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +40.8% compares to +16.5% for SPY (beat the market by 24.3%).
$10,000 invested 1 year ago→ $14,075 today
vs. S&P 500 (SPY) — same period beat market by 24.3%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($13.74)
✓Above 50-day MA ($16.72)
✓RSI(14) neutral zone (30–70) — currently 51.5
✓Positive return (+40.8%)
!Within 10% of period high (−17.7%)
Period Range $17.65
$9.82$21.45
RSI (14) 51.5
0 · OversoldOverbought · 100
Key Metrics
Price$17.65
Period Return+40.8%
Period High$21.45
Period Low$9.82
Drawdown−17.7%
MA-50$16.72
MA-200$13.74
RSI (14)51.5
Avg Volume (30d)1.9M
vs. SPYbeat by 24.3%
Return Rank#241 of 999
Trend Signals
Price is above the 200-day moving average ($13.74)